dc.contributor.author | Shukla, Nikunj M. | |
dc.contributor.author | Malladi, Subbalakshmi S. | |
dc.contributor.author | Day, Victor W. | |
dc.contributor.author | David, Sunil A. | |
dc.date.accessioned | 2017-05-04T19:20:48Z | |
dc.date.available | 2017-05-04T19:20:48Z | |
dc.date.issued | 2011-06-15 | |
dc.identifier.citation | Shukla, N. M., Malladi, S. S., Day, V., & David, S. A. (2011). Preliminary Evaluation of a 3H Imidazoquinoline Library as Dual TLR7/TLR8 Antagonists. Bioorganic & Medicinal Chemistry, 19(12), 3801–3811. http://doi.org/10.1016/j.bmc.2011.04.052 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/23896 | |
dc.description.abstract | Toll-like receptors (TLR) -7 and -8 are thought to play an important role in immune activation processes underlying the pathophysiology of HIV and several clinically important autoimmune diseases. Based on our earlier findings of TLR7-antagonistic activity in a 3H imidazoquinoline, we sought to examine a pilot library of 3H imidazoquinolines for dual TLR7/8 antagonists, since they remain a poorly explored chemotype. Two-dimensional NOE experiments were employed to unequivocally characterize the compounds. A quinolinium compound 12, bearing p-methoxybenzyl substituents on N3 and N5 positions was identified as a lead. Compound 12 was found to inhibit both TLR7 and TLR8 at low micromolar concentrations. Our preliminary results suggest that alkylation with electron-rich substituents on the quinoline N5, or conversely, elimination of the fixed charge of the resultant quaternary amine on the quinolinium may yield more active compounds. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | This article is made available under an Attribution-NonCommercial-NoDerivs 3.0 United States (CC BY-NC-ND 3.0 US) License. | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/us/ | en_US |
dc.subject | Toll-like receptor | en_US |
dc.subject | TLR7 | en_US |
dc.subject | TLR8 | en_US |
dc.subject | Imidazoquinoline | en_US |
dc.subject | NOESY | en_US |
dc.subject | HIV | en_US |
dc.subject | Autoimmune diseases | en_US |
dc.title | Preliminary Evaluation of a 3H Imidazoquinoline Library as Dual TLR7/TLR8 Antagonists | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Shukla, Nikunj M. | |
kusw.kuauthor | Malladi, Subbalakshmi S. | |
kusw.kuauthor | David, Sunil A. | |
kusw.kuauthor | Day, Victor | |
kusw.kudepartment | Medicinal Chemistry | en_US |
kusw.kudepartment | MSG-Xray Crystallography Lab | en_US |
kusw.oanotes | Per SherpaRomeo on 05/04/2017: Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing) Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing) Publisher's Version/PDF: cross author cannot archive publisher's version/PDF General Conditions: Authors pre-print on any website, including arXiv and RePEC Author's post-print on author's personal website immediately Author's post-print on open access repository after an embargo period of between 12 months and 48 months Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months Author's post-print may be used to update arXiv and RepEC Publisher's version/PDF cannot be used Must link to publisher version with DOI Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License | en_US |
dc.identifier.doi | 10.1016/j.bmc.2011.04.052 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC3114175 | en_US |
dc.rights.accessrights | openAccess | |